Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
United Sts Brent Oil Fd Lp Unit
BNO
5
United States Oil Fund LP
USO
US Stock MarketDetailed Quotes
Enanta Pharmaceuticals (ENTA)
- 13.500
- -0.020-0.15%
Close Aug 12 16:00 ET
393.19MMarket Cap-5.58P/E (TTM)
13.675High13.270Low149.82KVolume13.480Open13.520Prev Close2.02MTurnover0.76%Turnover RatioLossP/E (Static)29.13MShares17.15052wk High3.89P/B266.43MFloat Cap7.05052wk Low--Dividend TTM19.74MShs Float127.770Historical High--Div Yield TTM3.00%Range %4.090Historical Low13.493Avg Price1Lot Size
Enanta Pharmaceuticals (ENTA) News
All
Earnings
Transactions
Shareholding
Events
Other
10-Q: Enanta Pharmaceuticals | 10-Q: Q3 2026 Earnings Report
8-K: Enanta Pharmaceuticals | 8-K: Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
4: Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Rottinghaus Scott T.
8-K: Enanta Pharmaceuticals | 8-K: Current report
424B5: Enanta Pharmaceuticals | 424B5: Prospectus
8-K: Enanta Pharmaceuticals | 8-K: Current report
8-K: Enanta Pharmaceuticals | 8-K: Current report
S-8: Enanta Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
10-Q: Enanta Pharmaceuticals | 10-Q: Q2 2026 Earnings Report
8-K: Enanta Pharmaceuticals | 8-K: Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
SCHEDULE 13G/A: Enanta Pharmaceuticals | SCHEDULE 13G/A: Others
8-K: Enanta Pharmaceuticals | 8-K: Current report
4: Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry
4: Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Russell Lesley
4: Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Peterson Kristine
4: Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hata Yujiro S
4: Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director FOLETTA MARK G
4: Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director CARTER BRUCE L A
8-K: Enanta Pharmaceuticals | 8-K: Current report
EFFECT: Enanta Pharmaceuticals | EFFECT: Others
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
Ahead of the market open, US Treasury Secretary Bessent indicated that the United States and Iran are poised to reach an agreement the follo
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm